<DOC>
	<DOCNO>NCT00003187</DOCNO>
	<brief_summary>RATIONALE : Bone marrow transplantation may able replace immune cell destroy chemotherapy radiation therapy use kill cancer cell . Sometimes transplanted cell donor make immune response body 's normal cell . Eliminating T cell donor cell transplant may prevent happen . PURPOSE : Randomized phase II/III trial compare effectiveness conventional bone marrow transplantation T cell-depleted bone marrow transplantation treat patient leukemia , myelodysplasia , lymphoblastic lymphoma .</brief_summary>
	<brief_title>Bone Marrow Transplantation Treating Patients With Leukemia , Myelodysplasia , Lymphoblastic Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Compare disease free survival patient leukemia , myelodysplasia , lymphoblastic lymphoma treatment conventional ( non-T cell deplete ) T cell deplete unrelated donor bone marrow transplantation . II . Compare incidence primary secondary graft failure , acute chronic graft-vs-host disease , complication ( infection , veno-occlusive disease , interstitial pneumonitis ) , relapse patient treatment . III . Compare incidence malignancy , lymphoproliferative disorder , post-transplant myelodysplasia patient treatment . OUTLINE : This randomize , multicenter study . Patients stratify accord institution . Patients assign one two treatment arm , one conventional bone marrow transplantation ( arm I ) one T cell depletion bone marrow ( arm II ) . Arm I : Patients receive cyclophosphamide day -6 -5 . Total body irradiation ( TBI ) administer day -4 0 , although order may reverse . Males ALL receive testicular boost radiation therapy . Bone marrow infuse day 0 . Patients receive cyclosporine begin day -1 methotrexate IV day 1 , 3 , 6 , 11 . Arm II : T cell depletion conduct 2 different method , accord institution , treatment varies depend method use . Method I T10B9 depletion Method II counterflow elutriation depletion . Method I : Depending institution , patient receive TBI day -9 -7 ( chemotherapy ) ( Course I ) receive TBI day -3 -1 ( chemotherapy ) ( Course II ) . Course I also include cytarabine IV day -5 -3 , cyclophosphamide IV day -2 -1 , methylprednisolone IV day -2 0 5-18 . Bone marrow infusion administer day 0 . Cyclosporine begin day -1 . Course II include cytarabine IV day -7 -4 cyclophosphamide day -6 -5 . Methylprednisolone IV administer day -2 0 5-18 . Bone marrow infusion administer day 0 . Cyclosporine begin day 0 . Method II : Preparative therapy varies accord disease category . Acute lymphoblastic leukemia : Patients undergo TBI day -7 -4 . Males receive testicular boost day -7 , receive electron boost anterior posterior chest wall day -5 -4 . Cyclophosphamide IV administer day -3 -2 . Bone marrow infusion administer day 0 . Acute nonlymphocytic leukemia , chronic myelogenous leukemia , myelodysplastic syndrome : Patients receive cyclophosphamide IV day -7 -6 , follow TBI day -4 -1 . Bone marrow infusion administer day 0 . Patients receive methylprednisolone IV every 12 hr day -2 , -1 , 5-19 . Cyclosporine administered day -3 day 180 . All patient arm receive filgrastim ( granulocyte colony-stimulating factor ; G-CSF ) begin day 7 post-transplant . Patients follow weekly first 14 week , day 100 , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 560 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pathologically confirm acute myeloid leukemia Not first complete remission translocation ( 8 ; 21 ) unless fail first line induction therapy Not first complete remission translocation ( 15 ; 17 ) 16q abnormality unless : Failed first line induction therapy OR Molecular evidence disease Pathologically confirm acute lymphoblastic lymphoma ( ALL ) Not first complete remission OR High risk ALL first complete remission define : Hypodiploidy OR Pseudodiploidy translocation ( 9,22 ) , ( 4 ; 11 ) , ( 8 ; 14 ) OR Elevated WBC presentation Greater 100,000/mm3 612 month old Greater 50,000/mm3 1020 year old Greater 20,000/mm3 21 OR Failed achieve complete remission 4 week induction therapy Pathologically confirm chronic myelogenous leukemia ( CML ) blast crisis Pathologically confirm undifferentiated leukemia biphenotypic leukemia Pathologically confirm juvenile CML without either 7q infantile monosomy 7 Leukocytosis absolute monocytosis great 450 microliters AND Immature myeloid cell peripheral blood circulation Less 25 % marrow blast Myelodysplastic syndrome : Refractory anemia ( RA ) RA ring sideroblast RA excess blast ( RAEB ) RAEB transformation Chronic myelomonocytic leukemia Pathologically confirm stage IV lymphoblastic lymphoma No active CNS skin leukemic involvement No consenting suitably HLAmatched relate donor available Consenting unrelated donor available PATIENT CHARACTERISTICS : Age : 55 Performance status : Karnofsky 70100 % OR Lansky 60100 % Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Bilirubin le 2.5 mg/dL SGOT le 3 time upper limit normal Renal : Creatinine within normal range OR Creatinine clearance great 60 mL/min Cardiovascular : Asymptomatic OR Left ventricular ejection fraction rest great 40 % improve exercise Pulmonary : Asymptomatic OR DLCO great 45 % Other : Not pregnant lactate HIV negative No uncontrolled viral , bacterial , fungal infection PRIOR CONCURRENT THERAPY : Biologic therapy : No prior autologous allogeneic bone marrow transplant Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : No concurrent mediastinal radiation No prior radiation therapy would preclude total body irradiation Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>untreated childhood acute myeloid leukemia myeloid malignancy</keyword>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>